Targeting– tag –
-
Fate Therapeutics’ iPSC-Derived CAR T Therapy FT836 Shows Tumor Reduction and Favorable Safety Profile in KRASwt Colorectal Cancer Phase 1 Data at ASCO
GlobeNewswire (Fate Therapeutics Press Release) USA Overview Fate Therapeutics presented preliminary Phase 1 clinical data for its iPSC-derived, off-the-shelf CAR T-cell therapy, FT836, at the 2026 American Society of Clinical Oncology (... -
CRISPR Therapeutics to Detail Broadening Gene-Editing Pipeline at June Investor Conferences, Highlighting Approved Casgevy and Multidisease Programs
Market Chameleon USA Overview CRISPR Therapeutics announced plans to present its expanding gene-editing pipeline at three major investor conferences in early June 2026. The company will discuss the commercial progress of its approved gen... -
Allogene Therapeutics’ Anti-B7-H3 Allogeneic CAR γδ T Cell Therapy QH104 Shows Favorable Safety, Disease Stabilization in Leptomeningeal Metastasis Phase 1 Trial
PubMed USA Overview Allogene Therapeutics' anti-B7-H3 allogeneic CAR γδ T cell therapy, QH104, demonstrated a favorable safety profile and promising efficacy in a Phase 1 clinical trial for patients with leptomeningeal metastasis (LM) fr... -
The Future of Healing: Gene Therapy in 2026 Navigates CRISPR Advances and Access Challenges
薬事日報 Japan Overview By 2026, gene therapy is undergoing a paradigm shift, moving towards direct repair or replacement of disease-causing genes. CRISPR-based in vivo editing shows early clinical promise, pushing the vision of single-i... -
Advanced Lipid Nanoparticles Revolutionize Nucleic Acid and Gene-Editing Therapeutic Delivery
PMC (PubMed Central) USA Overview Lipid nanoparticles (LNPs) are becoming indispensable for efficient intracellular delivery of nucleic acid, mRNA, and gene-editing therapeutics, shielding them from degradation in circulation. Proven eff...
